BOSTON--(BUSINESS WIRE)--Life Biosciences Inc. announced today the appointment of two renowned scientists to senior positions at the pioneering company. Dr. John Amatruda has been appointed president of Life Laboratories, which provides central management and resources for drug discovery and development across Life Biosciences and its Daughter companies. Philip Lambert, PhD, has been named senior vice president, discovery and laboratories at Life Biosciences. Dr. Amatruda is also a member of Life Biosciences’ Scientific Advisory Board.
Life Biosciences is the first and largest company to address age-related decline (ARD) as a systemic breakdown of the body, rather than a series of isolated events and conditions. The two scientists will support all Life Biosciences’ Daughter companies, as they pursue their independent and collaborative research into the eight pathways of age-related decline.
“We are thrilled and privileged to have John and Phil on our team,” said Tristan Edwards, co-founder and chief executive officer of Life Biosciences. “Their exceptional and celebrated experience in both drug discovery and company-building will make them invaluable contributors to our mission.”
Throughout his 26-year career in drug research and development, Dr. Amatruda has produced drugs that treat diabetes and cardiovascular disease. In addition to tenures as a professor at Yale University School of Medicine and The University of Rochester School of Medicine, he co-founded the biotech company CohBar, served on numerous scientific advisory panels and boards of directors and was a Vice President at Bayer Corp. and a Senior Vice President at Merck Pharmaceuticals.
Dr. Lambert brings more than 25 years of experience in drug discovery and development to his role at Life Biosciences, as well as remarkable expertise in building companies and providing efficient and predictive preclinical drug discovery. Dr. Lambert comes to Life Biosciences from Charles River Laboratories where he was Head of Discovery Labs. Previously, Dr. Lambert co-founded and was Chief Scientific Officer at VivoPath, a contract research organization providing drug discovery solutions to the pharmaceutical and biotechnology community. Dr. Lambert brings a diverse perspective to his role at Life having held positions in biotechnology, large pharmaceutical companies, a non-profit, and contract research organizations.
Co-founded in 2017 by David Sinclair, PhD, AO, and Tristan Edwards, Life Biosciences is the first and largest company addressing the eight pathways of age-related decline (ARD) as a systemic breakdown of the body, not a series of isolated symptoms and conditions. It has established Daughter companies around the world, led by a Dream Team of respected scientists, to independently and collaboratively attack these pathways through pioneering research and product development. The company provides Daughter companies with the full resources of LifeLab, its 25,000 square-foot state-of-the-art research facility that includes a vivarium, robotics, and drug screening capabilities; and an emerging AI platform being developed by the company’s Lua subsidiary. Life Biosciences seeks to increase healthspans for everyone, including companion animals.
For more information on Life Biosciences, please visit www.lifebiosciences.com.